A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients with Advanced Systemic Mastocytosis
Study of CGT9486 in Patients with Advanced Systemic Mastocytosis (AdvSM)
Sponsor: Cogent Biosciences, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT8104
U.S. Govt. ID: NCT04996875
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the optimal dose of oral CGT9486 in patients with Advanced Systemic Mastocytosis (AdvSM) and to determine the efficacy of CGT9486 at the selected optimal dose in patients with Advanced Systemic Mastocytosis (AdvSM). This includes Aggressive Systemic Mastocytosis, Advanced Systemic Mastocytosis with an Associated Hematologic Neoplasm, or Mast Cell Leukemia.
This study is closed
Investigator
Mark Heaney, MD, PhD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with Advanced Systemic Mastocytosis (AdvSM)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE